TECVAYLI-daratumumab wins EU approval after cutting myeloma progression risk 83%
EU approval moves TECVAYLI plus daratumumab into earlier multiple myeloma treatment after Phase 3 data cut progression risk by 83.4%.
Pharma & Biotech
Pharma & Biotech
Rezatapopt Phase 2 enrollment completes as PMV targets 2027 ovarian cancer NDA
Rezatapopt completes key Phase 2 enrollment as PMV targets a Q1 2027 accelerated approval filing in TP53 Y220C ovarian cancer.
Pharma & Biotech
Can Tyvaso change the treatment pathway for idiopathic pulmonary fibrosis after TETON-1?
IPF has few durable treatment options. Tyvaso’s TETON data may test whether inhaled therapy can reset the regulatory and commercial playbook.
Pharma & Biotech
United Therapeutics targets 2026 FDA submission for Tyvaso IPF indication after TETON-2 success
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
Pharma & Biotech
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech's obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.